| Code | CSB-RA013263MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to lupartumab, designed for research targeting LYPD3 (LY6/PLAUR domain-containing protein 3), also known as C4.4A. LYPD3 is a glycosylphosphatidylinositol-anchored cell surface protein that plays important roles in cell adhesion, migration, and signal transduction. This protein is significantly overexpressed in various solid tumors, including non-small cell lung cancer, pancreatic cancer, and squamous cell carcinomas, where it contributes to tumor progression, metastasis, and poor prognosis. LYPD3 has emerged as a promising biomarker and therapeutic target in oncology research.
Lupartumab is a humanized IgG1 monoclonal antibody developed to target LYPD3-expressing cancer cells. This biosimilar provides researchers with a valuable tool for investigating LYPD3 biology, exploring its role in cancer pathogenesis, and evaluating potential therapeutic strategies in preclinical models. The antibody supports studies examining tumor cell behavior, invasion mechanisms, and antibody-based therapeutic approaches in LYPD3-positive malignancies.
There are currently no reviews for this product.